Representative Josh Gottheimer (D-New Jersey) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on January 24th.
Representative Josh Gottheimer also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
- Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
- Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
- Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.
Regeneron Pharmaceuticals Price Performance
REGN traded down $3.26 during trading on Wednesday, hitting $662.20. 530,473 shares of the company traded hands, compared to its average volume of 948,458. The company has a market cap of $72.77 billion, a PE ratio of 17.28, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $712.69 and its two-hundred day simple moving average is $903.47.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%.
Analysts Set New Price Targets
REGN has been the subject of a number of analyst reports. TD Cowen lowered their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.
Read Our Latest Stock Analysis on REGN
Institutional Trading of Regeneron Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Allstate Corp purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $2,276,000. Brown Brothers Harriman & Co. grew its stake in Regeneron Pharmaceuticals by 9.3% during the 4th quarter. Brown Brothers Harriman & Co. now owns 527 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 45 shares in the last quarter. DnB Asset Management AS grew its stake in Regeneron Pharmaceuticals by 8.1% during the 4th quarter. DnB Asset Management AS now owns 35,804 shares of the biopharmaceutical company’s stock valued at $25,504,000 after acquiring an additional 2,685 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 7.6% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 92,514 shares of the biopharmaceutical company’s stock valued at $65,900,000 after acquiring an additional 6,510 shares during the last quarter. Finally, New Age Alpha Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 59,271.4% in the 4th quarter. New Age Alpha Advisors LLC now owns 8,312 shares of the biopharmaceutical company’s stock worth $5,921,000 after purchasing an additional 8,298 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
- What Are Dividends? Buy the Best Dividend Stocks
- Shopify Confirms Stock Uptrend, New Highs in Sight
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.